Skip to main content
Clinical Trials/NCT00553072
NCT00553072
Completed
Phase 3

Magnesium Sulphate in Perinatal Asphyxia: A Randomized Placebo Controlled Trial.

Sheri Kashmir Institute of Medical Sciences1 site in 1 country40 target enrollmentSeptember 2004

Overview

Phase
Phase 3
Intervention
Magnesium sulphate
Conditions
Perinatal Asphyxia , Moderate to Severe HIE
Sponsor
Sheri Kashmir Institute of Medical Sciences
Enrollment
40
Locations
1
Primary Endpoint
good short term out come
Status
Completed
Last Updated
9 years ago

Overview

Brief Summary

Magnesium sulphate has been shown to be neuroprotective. The investigators hypothesize that magnesium sulphate infusion given to babies with perinatal asphyxia should improve outcome in the immediate neonatal period.

Detailed Description

Magnesium sulphate has a neuroprotective potential as has been shown by many studied in pregnant ladies with eclampsia where it helped neonates also and in mothers with preterm labour where the incidence of cerebral palsy was less. We designed a randomised controlled trial on 40 neonates with severe perinatal asphyxia to see whether it helps in the short term outcome of these neonates.

Registry
clinicaltrials.gov
Start Date
September 2004
End Date
August 2006
Last Updated
9 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Sheri Kashmir Institute of Medical Sciences
Responsible Party
Principal Investigator
Principal Investigator

Dr.Mushtaq

Professsor

Sheri Kashmir Institute of Medical Sciences

Eligibility Criteria

Inclusion Criteria

  • Babies eligible for the study were:
  • Term or post term
  • Less than 6 hours of age and had
  • severe perinatal asphyxia as manifested by any three of the following criteria.
  • History of fetal distress (late deceleration, Loss of beat to beat variability, fetal bradycardia, meconium stained amniotic fluid)
  • Need for immediate neonatal ventilation with bag and mask or through endotracheal intubation for 2 minutes or more after delivery
  • A 5-minute Apgar score of \< 6
  • Base deficit 15 mEq/L in cord blood or admission arterial or cord blood pH 4.Moderate to severe encephalopathy

Exclusion Criteria

  • Patients with severe IUGR
  • Any condition unrelated to asphyxia
  • Maternal prenatal magnesium administration
  • Metabolic disorder
  • Chromosomal anomalies; and
  • Congenital malformations were excluded from the study

Arms & Interventions

Magnesium sulphate, neurological outcome

Magnesium sulphate 250mg/kg after every 24 hours starting within 6 hours from birth

Intervention: Magnesium sulphate

Placebo

Placebo every 24 hours for 3 doses starting from 6 hours after birth

Intervention: Normal saline

Outcomes

Primary Outcomes

good short term out come

Time Frame: at discharge

Death and or abnormal neurological outcome at discharge

Secondary Outcomes

  • abnormal neurological examination and abnormal CT Head(at discharge)

Study Sites (1)

Loading locations...

Similar Trials